Published in Front Biosci (Landmark Ed) on January 01, 2011
An integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. Nat Cell Biol (2014) 2.45
Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology (2011) 1.64
Tumor-propagating cells and Yap/Taz activity contribute to lung tumor progression and metastasis. EMBO J (2014) 1.30
PI3K/AKT/mTOR and sonic hedgehog pathways cooperate together to inhibit human pancreatic cancer stem cell characteristics and tumor growth. Oncotarget (2015) 1.02
Intercellular adhesion: mechanisms for growth and metastasis of epithelial cancers. Wiley Interdiscip Rev Syst Biol Med (2011) 0.90
Embryonic signature in breast cancers; Pluripotency roots of cancer stem cells. Saudi Pharm J (2012) 0.81
Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival. World J Hepatol (2015) 0.79
Sarcoma stem cells: do we know what we are looking for? Sarcoma (2012) 0.79
Minnelide effectively eliminates CD133(+) side population in pancreatic cancer. Mol Cancer (2015) 0.76
Notch4+ cancer stem-like cells promote the metastatic and invasive ability of melanoma. Cancer Sci (2016) 0.76
Attenuation of lung cancer stem cell tumorigenesis and metastasis by cisplatin. Exp Lung Res (2014) 0.75
Detection of ALDH1 activity in rabbit hepatic VX2 tumors and isolation of ALDH1 positive cancer stem cells. J Transl Med (2016) 0.75
Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity. Cell Death Dis (2017) 0.75
Substrate Stiffness Influences Doxorubicin-Induced p53 Activation via ROCK2 Expression. Biomed Res Int (2017) 0.75
Unsaturated fatty acids regulate stemness of ovarian cancer cells through NF-κB. Stem Cell Investig (2017) 0.75
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell (2004) 7.22
Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol (2012) 3.65
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol (2013) 3.19
The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev (2008) 3.17
Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol (2012) 2.84
Bladder cancer. J Natl Compr Canc Netw (2013) 2.46
NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw (2009) 2.40
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol (2013) 2.29
Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol (2014) 2.19
Hematopoiesis is not clonal in healthy elderly women. Blood (2008) 1.95
Socio-demographic correlates of breast-feeding in urban slums of Chandigarh. Indian J Med Sci (2006) 1.94
Expression of cone-photoreceptor-specific antigens in a cell line derived from retinal tumors in transgenic mice. Invest Ophthalmol Vis Sci (2004) 1.92
NCCN clinical practice guidelines in oncology: testicular cancer. J Natl Compr Canc Netw (2009) 1.86
CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. Cancer Res (2010) 1.78
Subunit 6 of the COP9 signalosome promotes tumorigenesis in mice through stabilization of MDM2 and is upregulated in human cancers. J Clin Invest (2011) 1.54
Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability. Proc Natl Acad Sci U S A (2011) 1.51
A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. Cancer Cell (2010) 1.49
Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J Neurooncol (2009) 1.48
Kinase-dependent differentiation of a retinal ganglion cell precursor. Invest Ophthalmol Vis Sci (2006) 1.47
Increased sensitivity to UV radiation in mice with a p53 point mutation at Ser389. Mol Cell Biol (2004) 1.44
Hsp27 upregulation by HIF-1 signaling offers protection against retinal ischemia in rats. Invest Ophthalmol Vis Sci (2005) 1.40
Repression of Six3 by a corepressor regulates rhodopsin expression. Proc Natl Acad Sci U S A (2007) 1.38
Oxidative stress in glaucoma: a burden of evidence. J Glaucoma (2007) 1.36
Induced autoimmunity to heat shock proteins elicits glaucomatous loss of retinal ganglion cell neurons via activated T-cell-derived fas-ligand. J Neurosci (2008) 1.30
Elevated hydrostatic pressure triggers mitochondrial fission and decreases cellular ATP in differentiated RGC-5 cells. Invest Ophthalmol Vis Sci (2007) 1.30
Mdm2 and Mdm4 loss regulates distinct p53 activities. Mol Cancer Res (2008) 1.27
The sigma receptor ligand (+)-pentazocine prevents apoptotic retinal ganglion cell death induced in vitro by homocysteine and glutamate. Brain Res Mol Brain Res (2004) 1.23
Light induces programmed cell death by activating multiple independent proteases in a cone photoreceptor cell line. Invest Ophthalmol Vis Sci (2007) 1.13
Retinal ganglion cell line apoptosis induced by hydrostatic pressure. Brain Res (2006) 1.12
Serum deprivation induces apoptotic cell death of transformed rat retinal ganglion cells via mitochondrial signaling pathways. Invest Ophthalmol Vis Sci (2005) 1.11
Testicular cancer. J Natl Compr Canc Netw (2012) 1.11
Analysis of sigma receptor (sigmaR1) expression in retinal ganglion cells cultured under hyperglycemic conditions and in diabetic mice. Brain Res Mol Brain Res (2002) 1.10
Interleukin-10 receptor signaling through STAT-3 regulates the apoptosis of retinal ganglion cells in response to stress. Invest Ophthalmol Vis Sci (2003) 1.10
Role of PPAR-gamma ligands in neuroprotection against glutamate-induced cytotoxicity in retinal ganglion cells. Invest Ophthalmol Vis Sci (2003) 1.09
OPA1 expression in the normal rat retina and optic nerve. J Comp Neurol (2005) 1.06
Calpeptin provides functional neuroprotection to rat retinal ganglion cells following Ca2+ influx. Brain Res (2006) 1.06
Kidney cancer. J Natl Compr Canc Netw (2011) 1.06
Soluble CD44 is cytotoxic to trabecular meshwork and retinal ganglion cells in vitro. Invest Ophthalmol Vis Sci (2005) 1.02
A glaucoma-associated mutant of optineurin selectively induces death of retinal ganglion cells which is inhibited by antioxidants. Invest Ophthalmol Vis Sci (2007) 1.02
Kidney cancer, version 2.2014. J Natl Compr Canc Netw (2014) 0.98
Metabolic syndrome: a challenging health issue in highly urbanized Union Territory of north India. Diabetol Metab Syndr (2010) 0.97
Penile cancer: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2013) 0.97
Levels of fatigue and distress in senior prostate cancer survivors enrolled in a 12-week randomized controlled trial of Qigong. J Cancer Surviv (2013) 0.96
Multidrug-resistant MCF-7 breast cancer cells contain deficient intracellular calcium pools. Breast Cancer Res Treat (2002) 0.96
The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. Target Oncol (2013) 0.95
Sequencing systemic therapies for metastatic kidney cancer. Curr Treat Options Oncol (2015) 0.95
Methylation of AR locus does not always reflect X chromosome inactivation state. Blood (2012) 0.93
The role of CaMKII in BDNF-mediated neuroprotection of retinal ganglion cells (RGC-5). Brain Res (2005) 0.92
Neuroprotective effects of minocycline against in vitro and in vivo retinal ganglion cell damage. Brain Res (2005) 0.92
Metastasis suppressor KISS1 seems to reverse the Warburg effect by enhancing mitochondrial biogenesis. Cancer Res (2013) 0.91
Heat shock protein 27 delays Ca2+-induced cell death in a caspase-dependent and -independent manner in rat retinal ganglion cells. Invest Ophthalmol Vis Sci (2005) 0.91
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer. Clin Cancer Res (2013) 0.91
Mutant p53 gain of oncogenic function: in vivo evidence, mechanism of action and its clinical implications. Fukuoka Igaku Zasshi (2009) 0.90
Empirically identified goals for the management of unexplained symptoms. Fam Med (2006) 0.90
Management of cancer-associated thrombotic microangiopathy: what is the right approach? Am J Hematol (2007) 0.90
A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. Cancer (2014) 0.90
Trp53 negatively regulates autoimmunity via the STAT3-Th17 axis. FASEB J (2011) 0.90
Microarray reveals complement components are regulated in the serum-deprived rat retinal ganglion cell line. Mol Vis (2007) 0.89
Metabolic complications with the use of mTOR inhibitors for cancer therapy. Cancer Treat Rev (2013) 0.89
IMRT with simultaneous integrated boost and concurrent chemotherapy for locoregionally advanced squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys (2010) 0.88
Management of castrate resistant prostate cancer-recent advances and optimal sequence of treatments. Curr Urol Rep (2013) 0.88
A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. BJU Int (2014) 0.86
Testicular Cancer, Version 2.2015. J Natl Compr Canc Netw (2015) 0.86
Retinal ganglion cell death and neuroprotection: Involvement of the CaMKIIalpha gene. Brain Res Mol Brain Res (2005) 0.85
Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design. Clin Genitourin Cancer (2013) 0.85
Comparison of acute toxicity and mortality after two different dosing regimens of high-dose interleukin-2 for patients with metastatic melanoma. Target Oncol (2013) 0.85
Recent advances in immunotherapy for the treatment of prostate cancer. Expert Opin Biol Ther (2011) 0.85
Role of nonfeminizing estrogen analogues in neuroprotection of rat retinal ganglion cells against glutamate-induced cytotoxicity. Free Radic Biol Med (2005) 0.85
A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer. J Natl Compr Canc Netw (2012) 0.85
Molecular-wire behavior of OLED materials: exciton dynamics in multichromophoric Alq3-oligofluorene-Pt(II)porphyrin triads. J Am Chem Soc (2006) 0.84
Novel molecular aberrations and pathologic findings in a tubulocystic variant of renal cell carcinoma. Indian J Pathol Microbiol (2014) 0.84
Prostate cancer risk prediction based on complete prostate cancer family history. Prostate (2014) 0.84
Emerging molecularly targeted therapies in castration refractory prostate cancer. Prostate Cancer (2013) 0.83
Patient and provider attitudes toward genomic testing for prostate cancer susceptibility: a mixed method study. BMC Health Serv Res (2013) 0.83
A population-based analysis of clustering identifies a strong genetic contribution to lethal prostate cancer. Front Genet (2013) 0.83
Clinical profile of epilepsy, in a tertiary care centre of North-west India. J Indian Med Assoc (2011) 0.82
An unusual cause of psychosis. Lancet (2004) 0.82
Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer (2014) 0.82
Coronary cameral fistula treated by the Amplatzer vascular plug. Jpn J Radiol (2014) 0.82
A novel link between the HER2-Akt and MDM2-p53 pathways via CSN6. Cell Cycle (2012) 0.82
Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinoma. J Immunother (2014) 0.81
Activin receptor inhibitors--dalantercept. Curr Oncol Rep (2015) 0.81
Community physicians' strategies for patients with medically unexplained symptoms. Fam Med (2008) 0.81
Feasibility and acceptability of a Tai Chi Chih randomized controlled trial in senior female cancer survivors. Integr Cancer Ther (2013) 0.81
Novel exon 2 α spectrin mutation and intragenic crossover: three morphological phenotypes associated with four distinct α spectrin defects. Haematologica (2013) 0.80
Ipilimumab in the treatment of prostate cancer. Future Oncol (2015) 0.80
Differing leukocyte gene expression profiles associated with fatigue in patients with prostate cancer versus chronic fatigue syndrome. Psychoneuroendocrinology (2013) 0.80
Blood pressure, salivary cortisol, and inflammatory cytokine outcomes in senior female cancer survivors enrolled in a tai chi chih randomized controlled trial. J Cancer Surviv (2014) 0.80
Photoreceptor cell apoptosis induced by the 2-nitroimidazole radiosensitizer, CI-1010, is mediated by p53-linked activation of caspase-3. Neurotoxicology (2005) 0.79
Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis. Target Oncol (2013) 0.79
Nipradilol protects rat retinal ganglion cells from apoptosis induced by serum deprivation in vitro and by diabetes in vivo. Curr Eye Res (2008) 0.79
MDM2 binding protein, a novel metastasis suppressor. Cancer Metastasis Rev (2012) 0.78
Improvement of psoriasis during sunitinib therapy for renal cell carcinoma. Am J Med Sci (2010) 0.78
Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors. Invest New Drugs (2015) 0.78
MTBP inhibits migration and metastasis of hepatocellular carcinoma. Clin Exp Metastasis (2015) 0.77
Obesity and treatment of prostate cancer: what is the right dose of Lupron Depot? Clin Cancer Res (2007) 0.77
Successful management with intravenous immunoglobulins of acquired von Willebrand disease associated with monoclonal gammopathy of undetermined significance. Ann Intern Med (2004) 0.77